Tositumomab/iodine-131 tositumomab (Bexxar) is a radioimmunotherapeutic agent in development for patients with low-grade or transformed non-Hodgkin’s lymphoma (NHL). This analysis focuses
J. P. Leonard
Advertisement
Articles by J. P. Leonard
Relapsed or refractory low-grade non-Hodgkin’s lymphoma (NHL) and transformed low-grade NHL are incurable diseases. Tositumomab/iodine-131 tositumomab (Bexxar) is a novel
Advertisement
Latest Updated Articles
- Iodine-131 Tositumomab for Patients With Low-Grade or Transformed Low-Grade Non-Hodgkin’s Lymphoma: Complete Response Data
Published: March 1st 2001 | Updated:
- Efficacy and Safety of Tositumomab/Iodine-131 Tositumomab in the Expanded Access Study: Interim Report From Two Institutions
Published: March 1st 2001 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?
2
Trial Assessing Savolitinib/Osimertinib in NSCLC Completes Enrollment
3
Searching for Synergy in Liver-Dominant Neuroendocrine Tumors
4
Neoadjuvant Nivolumab/Ipilimumab Shows Superior EFS in Resectable Melanoma
5
